PartnershipAug 12, 2026, 04:15 PM
ArriVent BioPharma inks ARR-002 license for Greater China; up to $80.6M
AI Summary
ArriVent BioPharma entered into a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals Co., Ltd. for the exclusive development and commercialization of ARR-002 in Greater China, potentially yielding up to $80.6 million in payments and tiered royalties. The company also reported its second quarter 2026 financial results, with cash and investments of $373.1 million, expected to fund operations into 2028. Key pipeline advancements include firmonertinib Phase 3 data expected in 2H 2026 and ARR-002 first patient dosing in Q3 2026.
Key Highlights
- Granted Shanghai Allist Pharmaceuticals an exclusive license for ARR-002 in Greater China.
- Potential payments up to $80.6 million from Allist, including upfront and milestones, plus tiered royalties.
- Cash and investments totaled $373.1 million as of June 30, 2026.
- Expected cash runway into 2028.
- Net loss for Q2 2026 was $49.9 million.
- Research and development expenses for Q2 2026 were $42.3 million.
- Topline global pivotal Phase 3 data for firmonertinib expected in 2H 2026.
- First patient dosing for ARR-002 in a Phase 1 trial expected in Q3 2026.
Price Impact
More from AVBP